SCHEMBL5367987

SCHEMBL5367987

Cc1cc(C2(O)CCN(C(=O)O)CC2)ccc1F

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.42
CASP6 P55212 1/20 0.42
CCR1 P32246 1/20 0.40
KDM4E B2RXH2 1/20 0.40
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
DRD3 P35462 1/20 0.40
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
S1PR2 O95136 3/20 0.39
ALDH1A1 P00352 2/20 0.39
RORC P51449 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5379982 0.89 AKR1B10 (0.47) POLBCCR1S1PR2ALDH1A1RORC
SCHEMBL3384526 0.87 DRD2 (0.45) CCR1KDM4EDRD2DRD4DRD3
SCHEMBL5376169 0.87 POLB (0.46) POLBKDM4EDRD2DRD4DRD3
SCHEMBL5375143 0.83 KDM4E (0.43) POLBCCR1KDM4EDRD2DRD4
SCHEMBL5380104 0.83 CCR1 (0.50) CCR1KDM4EDRD2DRD4DRD3
SCHEMBL5378220 0.81 POLB (0.44) POLBCCR1KDM4EDRD2DRD4
SCHEMBL8418296 0.81 POLB (0.45) POLBCASP6DRD2HDAC3HDAC1
SCHEMBL3860368 0.81 OPRL1 (0.46) DRD2DRD4DRD3S1PR2
SCHEMBL5381232 0.80 CCR1 (0.50) CCR1KDM4EDRD2DRD4DRD3
SCHEMBL3851628 0.80 OPRM1 (0.45) POLBDRD2DRD4DRD3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1714961-B1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2015-12-09 EP claimed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US claimed
EP-1714961-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2006-10-25 EP claimed
EP-1714961-B1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2015-12-09 EP disclosed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US disclosed
EP-1714961-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2006-10-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173537-A1 Indazole compound and pharmaceutical use thereof CYP3A5, CYP3A43, TP53 POLB 1826/4885CASP6 1341/4885CCR1 3991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.